Paradigm Shift Intervention Monitoring
twitter
Commentary
CIDRAP Myth On
Beta2c
Coronavirus & HPIV-2 In UK Cluster
Recombinomics
Commentary 17:00
March 17, 2013
Today's report said the man who died had an underlying malignant condition and had been receiving treatment that likely resulted in immunosuppression. Tests found type 2 parainfluenza virus as well as NCoV in his nose and throat swabs. The woman recovered from her illness after 9 days, and tests also detected type 2 parainfluenza virus in her sputum sample, according to HPA investigators.
The above comments (in red) from HPA paper describe the testing of the confirmed mild nCoV case (30F) in the UK. As noted, two distinct samples were tested, and only the sputum sample (lower respiratory tract collected on February 13) tested positive for nCoV. In contrast, the type 2 parainfluenza virus (HPIV-2) was only detected in the upper respiratory tract sample (nose and throat swab collected on February 15).
The failure to detect nCoV in an upper respiratory sample from an nCoV case highlights the limitations of the nCoV testing of the milder cases and the fatal flaw in the WHO claims that there is no sustained transmission of nCoV (base on false negatives). In the CIDRAP media report on the HPA Eurosurveillance paper, the failure to detect nCoV in the upper respiratory tract is not noted, and the HPIV-2 was said to be detected in the sputum sample (in blue), when in fact the detection was in the nose and throat swab.
Thus, the CIDRAP report leads to media myths, which are widely published, with associated confusion on nCoV transmission, including fatal flaws by the ECDC, which based its nCoV risk assessment on negative data on mild cases linked to contact with confirmed nCoV cases. These fatally flawed positions also ignore the close relationship between all 5 human nCoV sequences, which are easily distinguished from all published bat sequences as well as striking similarities between nCoV and SARS-CoV.
CIDRAP should issue a clarification on the detection (as well as lack of detection) of nCoV and HPIV-2 in upper and lower respiratory tract samples from this important cluster.
Recombinomics
Presentations
Recombinomics
Publications
Recombinomics
Paper
at Nature Precedings